Livraison GRATUITE dès 20€
+ 3000 clients satisfaits
Comblé ou remboursé
Service Client réactif
Paiements 100% sécurisés

Psilocybin Trial for Bipolar Depression: Promising Results

Psilocybin Trial for Bipolar Depression: Promising Results

In a groundbreaking clinical trial, the first trial of psilocybin for the treatment of treatment-resistant bipolar IIdepression has shown promising results. The trial, conducted at Sheppard Pratt and published in JAMA Psychiatry , explores the effectiveness and safety of a single dose of synthetic psilocybin accompanied by psychotherapy in treating people with treatment-resistant bipolar II disorder. The trial results are encouraging, with 80% of participants meeting remission criteria 12 weeks after treatment .

The Psilocybin Study for Bipolar Depression

The 12-week open-label trial was initiated and led by Scott T. Aaronson, scientific director of the Institute for Advanced Diagnostics and Therapies at Sheppard Pratt. The study included 15 participants aged 18 to 65 with treatment-resistant bipolar II disorder . Each participant had experienced an episode of bipolar II disorder for a period greater than three months and had documented at least two unsuccessful pharmacological treatments during the current episode.

Psilocybin bipolar depression study

Psilocybin Treatment Protocol

Trial participants have:

  1. Stopped psychotropic medications at least two weeks before
  2. Received a single dose of synthetic psilocybin COMP360 (25 mg) in a controlled setting.
  3. Therapists held sessions with patients throughout the day .
  4. Three sessions were conducted before the start of the trial , and three integration sessions took place after the treatment.
  5. Funding for the study will also monitor patient outcomes for two years after treatment.

Encouraging results from taking Psilocybin

The results of the trial are very encouraging:

  • One participant described the transformation she experienced as taking a deep breath after breathing through a straw for years.
  • Many people who struggled with bipolar II disorder for years and had lost hope of treatment have reported similar stories.
  • In this small pilot study, no patients developed psychotic symptoms during treatment, and 73% of participants met criteria for remission according to the Montgomery Asberg Depression Scale three weeks after treatment.


Long-Term Remission on Psilocybin Treatment for Bipolar Treatment

Even more remarkable, 80% of participants experienced remission without an increase in bipolar II disorder symptoms such as mania , hypomania , or suicidality twelve weeks after treatment. These results suggest not only the effectiveness of psilocybin in the treatment of bipolar II depression, but also its safety. It is important to note that the results of this study cannot be extrapolated to the study of psilocybin in the treatment of bipolar I disorder.

Conclusion

The first trial of psilocybin for the treatment of treatment-resistant bipolar II depression has shown promising results. With 80% of participants meeting remission criteria 12 weeks after treatment, this groundbreaking study indicates the potential of psilocybin in the treatment of bipolar II depression . Although more research is needed, these findings give hope to people who have struggled with this disorder for years. Psilocybin could offer an effective new treatment route and improve the quality of life of people with treatment-resistant bipolar II disorder.

FAQs

1. How Significant Is This Trial Of Psilocybin For Bipolar Depression?

- This trial is the first of its kind and has shown promising results in the treatment of treatment-resistant bipolar II disorder.

2. How many participants were included in the study?

- The study included 15 participants aged 18 to 65 with treatment-resistant bipolar II disorder.

3. What were the participant selection criteria?

- Participants had to have experienced an episode of bipolar II disorder for a period greater than three months and have documented at least two unsuccessful pharmacological treatments during the current episode.

4. What was the dosage of psilocybin administered to the participants?

- Participants received a single dose of synthetic psilocybin COMP360 (25 mg) in a controlled setting.

5. What were the results of the trial?

- 80% of participants met the criteria for remission 12 weeks after treatment, with no increase in symptoms of bipolar II disorder.

6. Did any participants develop psychotic symptoms during treatment?

- There were no findings indicating that patients developed psychotic symptoms during treatment.

7. How long were participants monitored after treatment?

- Study funding made it possible to monitor patient outcomes for two years after treatment.

8. Can the results of this study apply to bipolar I disorder?

- The results of this study suggest the effectiveness and safety of psilocybin in the treatment of bipolar II depression, but cannot be extrapolated to the study of psilocybin in the treatment of bipolar I disorder.

9. What did a participant compare her experience to?

- One participant compared the transformation she experienced to taking a deep breath after breathing through a straw for years.

10. What is the next step after this trial?

- Further research is needed to explore the potential of psilocybin in the treatment of bipolar II depression and expand the scope of its use in the treatment of mental health disorders.

Disclaimer/Important Notice

This study on the use of psilocybin in the treatment of bipolar II depression offers promising results that are generating significant interest. However, it is imperative to point out that the use of psilocybin is currently banned in most countries. The results of this research in no way justify the self-administration of psilocybin or similar substances.

It is strongly recommended to consult a healthcare professional before undertaking any treatment involving psychoactive substances. Authorization and medical supervision are essential to ensure the safety and effectiveness of the treatment.

The information provided in this study is intended for informational and research purposes only. They should in no way replace professional medical advice, diagnosis or treatment. Individuals interested in innovative treatments, such as those involving psilocybin, should participate in clinical studies under the supervision of qualified healthcare professionals.


0 comment
Leave a comment

Please note, comments must be approved before they are published.

Good manufacturing practice (BPF) or GMP, this logo guarantees the quality, safety and conformity of the products manufactured.

Third-party lab testing involves having products analyzed by an independent company to verify their quality .

Organic hemp is a type of hemp grown sustainably without the use of pesticides or chemical fertilizers .

Organic Ingredient: Naturally grown, chemical-free and eco-friendly product.

This site uses cookies to ensure you get the best experience on our site.